Avinger, Inc. (NASDAQ:AVGR) Sees Significant Decline in Short Interest

Avinger, Inc. (NASDAQ:AVGR) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 166,300 shares, a decrease of 29.1% from the December 31st total of 234,700 shares. Based on an average trading volume of 2,170,000 shares, the short-interest ratio is presently 0.1 days. Approximately 6.0% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Avinger in a report on Wednesday. They set a “hold” rating on the stock.

Avinger Stock Down 4.2 %

Shares of NASDAQ:AVGR traded down $0.03 during trading on Friday, hitting $0.58. 303,114 shares of the company traded hands, compared to its average volume of 903,613. The business’s fifty day moving average is $0.74 and its 200-day moving average is $0.97. The stock has a market capitalization of $1.90 million, a price-to-earnings ratio of -0.05 and a beta of 1.15. Avinger has a one year low of $0.39 and a one year high of $5.45.

Avinger (NASDAQ:AVGR) last issued its earnings results on Thursday, November 7th. The medical device company reported ($1.82) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.21. Avinger had a negative return on equity of 5,527.11% and a negative net margin of 261.06%. The firm had revenue of $1.65 million for the quarter, compared to analyst estimates of $1.60 million. During the same period last year, the company earned ($2.92) earnings per share. On average, analysts forecast that Avinger will post -4.69 EPS for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.